category,datetime,headline,id,image,related,source,summary,url
company,1768170600,Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion,138068851,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,"CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc",https://finnhub.io/api/news?id=75960b0138e2424bbca8b394a2f8ecb84d7afc9c5fc971f2a912f8ee845eacac
company,1768147380,This ETF Is Proof That the Healthcare Rebound Is Real,138075157,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,"Track healthcareâ€™s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.",https://finnhub.io/api/news?id=37f4d5b38f1ff502010ff587add70bfce19fea47b3f9d689eddcb7adcf089fbb
company,1768114660,"Novo Nordisk: Investor Confidence Up, But Caution Needed",138062829,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536,PFE,SeekingAlpha,"Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair valuation. See why NVO stock is a hold.",https://finnhub.io/api/news?id=0d1620b04f650690355e85bf9e3c1b0e05b7a1cdf359071b344da6fd9e26b352
